Royce & Associates LP Jounce Therapeutics, Inc. Transaction History

Royce & Associates LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 11, 2019	SELL	$2.69 - $6.71 $7,260 - $18,110	-2,699 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$6.5 - $8.37 $8,586 - $11,056	1,321 Added 95.86%	2,699 $18,000
Q2 2018 Aug 09, 2018	BUY	$7.27 - $21.88 $10,018 - $30,150	1,378 New	1,378 $11,000
Q1 2018 May 14, 2018	SELL	$13.4 - $28.4 $7,879 - $16,699	-588 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$12.52 - $17.82 $1,026 - $1,461	82 Added 16.21%	588 $7,000
Q3 2017 Nov 13, 2017	BUY	$11.17 - $16.99 $5,652 - $8,596	506	506 $8,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

Stay updated on Royce & Associates LP with notifications on news.